RxDoctor Payments Data

Fahima Azizi, MD

Hospitalist · Hagerstown, MDNPI 1477865814

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Novo Nordisk at 24.4% of the total. Among hospitalist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,777in general payments, 2019–2025

Across 130 payments — averaging $21.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$678
  • AstraZeneca$405
  • Exact Sciences$246
  • Astellas Pharma US Inc$195
  • Johnson & Johnson$162
  • Daiichi Sankyo Inc.$159
  • plus $933 from 21 others

What the payments were for

  • Food & beverage$2,777100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,777 in reported general payments places this provider in the 95th percentile of 414 hospitalist providers in Maryland.

See all hospitalist providers in Maryland

Medicare billing

Part B allowed, 2024
$85,009
Medicare patients
183
Services billed
998

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$63,400
EliquisApixaban33$25,278
Trijardy XrEmpaglifloz/Linaglip/Metformin11$16,998
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$14,882
Azelastine Hcl32$944
Levothyroxine Sodium56$838
Atorvastatin Calcium100$785
Albuterol Sulfate HfaAlbuterol Sulfate38$751
Nifedipine ErNifedipine13$715
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$600
Rosuvastatin Calcium47$576
Amlodipine Besylate69$575
Gabapentin41$529
Pregabalin28$478
ValacyclovirValacyclovir Hcl17$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$678$63,40050 claims
PfizerEliquis$103$25,27833 claims
Boehringer IngelheimTrijardy Xr$81$16,99811 claims
GSKTrelegy Ellipta$86$14,88218 claims
Almatica Pharma LLCSertraline Hcl$20$10325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 414 hospitalist providers in Maryland.

Other hospitalist in Hagerstown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →